.jpg)
.png)
Last Updated: Thursday, 16-May-2019 19:00:00 EDT
Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the U.S. Food and Drug Administraion (FDA) has approved Praluent® (alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease.
Last Updated: Thursday, 16-May-2019 18:00:00 EDT
WAYLIVRA, the only therapy available for Familial Chylomicronemia Syndrome (FCS), has been authorized as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis whose response to diet and triglyceride-lowering therapy has been inadequate, according to a May 7 press release issued by Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
Last Updated: Thursday, 16-May-2019 19:15:00 EDT
MIAMI, Fla. – (May 16, 2019) – Findings of the first patient statin use survey based on a comprehensive set of patient experiences and behavioral markers were presented today at the National Lipid Association’s (NLA) 2019 Scientific Sessions.
Last Updated: Thursday, 16-May-2019 19:15:00 EDT
MIAMI, Fla. – (May 16, 2019) – The NLA has released a statement paper that provides updated guidance to clinicians to help identify patient groups in whom treatment with PCSK9 monoclonal antibodies (mAbs) provides a reasonable value.
Article By:
JOYCE L. ROSS, MSN, CRNP, CLS, FPCNA, FNLA
Past President, National Lipid Association
Consultative Education Specialist, Cardiovascular Risk Intervention
University of Pennsylvania Health System - Retired
Philadelphia, PA
We have come a very long way along the road of understanding the pathophysiology of cardiovascular vascular disease. Historical theories regarding atherogenesis proposed in the 19th century are now being validated.
Article By:
KAYE-EILEEN WILLARD, MD, FNLA
Editor, LipidSpin
Medical Director, Lipid Clinic and Physician Advisor
Ascension Wisconsin All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology
“They may forget your name, but they will never forget how you made them feel.”
- Maya Angelou
Article By:
JUDITH COLLINS, MSN, APRN-BC, CVN-BC, FPCNA, CLS, FNLA
Cardiovascular Nurse Practitioner
Montrose Cardiology
Montrose, CO
Last Updated: Monday, 29-Apr-2019 13:00:00 EDT
The NLA released an official scientific statement on Lipoprotein(a) [Lp(a)] designed as a comprehensive source of guidance for medical professionals making decisions to improve the health and well-being of children and adults at risk of premature cardiovascular disease.
Last Updated: Friday, 12-Apr-2019 17:00:00 EDT
JACKSONVILLE, Fla. (April 12, 2019) — The 2019 National Lipid Association Nominating Committee released its annual report and recommendations on Monday.
Last Updated: Friday, 12-Apr-2019 12:15:00 EDT
Pursuant to the advice of the Chapter of the National Lipid Association, the following updates to the Bylaws are proposed to the NLA membership for adoption at the NLA Business Meeting on May 18, 2019. The purpose of the update is to restore the position of the at-large directors on the chapter boards of directors and eliminate the regional representative position. You may review the proposed changes by downloading the document at the link below.